Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
AnaptysBio, Inc. (ANAB) - free report >>
Autolus Therapeutics PLC Sponsored ADR (AUTL) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AnaptysBio, Inc. (ANAB) - free report >>
Autolus Therapeutics PLC Sponsored ADR (AUTL) - free report >>
Image: Bigstock
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
Autolus Therapeutics PLC Sponsored ADR (AUTL - Free Report) shares soared 6.3% in the last trading session to close at $6.38. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 17.7% loss over the past four weeks.
The sudden surge in the stock price can be attributed to the positive investor mindset regarding Autolus’ CAR T cell pipeline. The company is also currently looking to advance and expand the same through strategic initiatives. Last week, the company announced entering into a collaboration agreement with BioNTech, remaining eligible to receive up to $250 million from the latter. The strategic alliance is expected to leverage manufacturing and commercial infrastructure as well as technology to advance both companies’ autologous CAR-T programs toward commercialization, pending market authorization.
This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of -8.7%. Revenues are expected to be $0.3 million, down 92.2% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Autolus Therapeutics PLC Sponsored ADR, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on AUTL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Autolus Therapeutics PLC Sponsored ADR belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, AnaptysBio, Inc. (ANAB - Free Report) , closed the last trading session 0.5% lower at $23.01. Over the past month, ANAB has returned 0.5%.
AnaptysBio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.72. Compared to the company's year-ago EPS, this represents a change of -85%. AnaptysBio, Inc. currently boasts a Zacks Rank of #3 (Hold).